PS06.03 INSIGHT Study Interim Analysis: Impact of VeriStrat Results on Patient Management in Early and Locally Advanced NSCLC: Topic: Medical Oncology

P.R. Walker; E. Schaefer; P. Thompson Rich; J. Dubay; N. Ikhlaque; D. Oubre; E. Pauli; J. Orsini; E. Santos; A. Veatch Rose; C. Jordan; R. Page; A. Arnaud; B. Mitchell

doi:10.1016/J.JTHO.2017.09.084

PS06.03 INSIGHT Study Interim Analysis: Impact of VeriStrat Results on Patient Management in Early and Locally Advanced NSCLC: Topic: Medical Oncology

P.R. Walker
, E. Schaefer
, P. Thompson Rich
, J. Dubay
, N. Ikhlaque
, D. Oubre
, E. Pauli
, J. Orsini
, E. Santos
, A. Veatch Rose
, C. Jordan
, R. Page
, A. Arnaud
, B. Mitchell

East Carolina University
Highlands Oncology Group, Fayetteville, AR/US
CTCA at Southeastern Regional Medical Center, Zion, IL/US
DCH Cancer Centers, Tuscaloosa, AL/US
Franciscan St. Francis Health, Indianapolis, IN/US
Ponchartrain Hematology Oncology, Hammond, LA/US
Clearview Cancer Institute, Huntsville, AL/US
Essex Oncology Group of North Jersey, Belleville, NJ/US
Lynn University
Northwest Medical Specialties, Puyallup, WA/US
JPS Cancer Center, Fort Worth, TX/US
The Center for Cancer & Blood Disorders, Fort Worth, TX/US
Biodesix, Inc, Boulder, CO/US
Virginia Cancer Institute, Richmond, VA/US

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Thoracic Oncology
Volume	12
Issue number	11
DOIs	https://doi.org/10.1016/J.JTHO.2017.09.084
State	Published - Nov 1 2017
Externally published	Yes

Disciplines

Medicine and Health Sciences
Medical Biophysics
Oncology
Internal Medicine

Access to Document

10.1016/J.JTHO.2017.09.084License: Unspecified

Cite this

Walker, P. R., Schaefer, E., Rich, P. T., Dubay, J., Ikhlaque, N., Oubre, D., Pauli, E., Orsini, J., Santos, E., Rose, A. V., Jordan, C., Page, R., Arnaud, A., & Mitchell, B. (2017). PS06.03 INSIGHT Study Interim Analysis: Impact of VeriStrat Results on Patient Management in Early and Locally Advanced NSCLC: Topic: Medical Oncology. Journal of Thoracic Oncology, 12(11). https://doi.org/10.1016/J.JTHO.2017.09.084

Walker, PR, Schaefer, E, Rich, PT, Dubay, J, Ikhlaque, N, Oubre, D, Pauli, E, Orsini, J, Santos, E, Rose, AV, Jordan, C, Page, R, Arnaud, A & Mitchell, B 2017, 'PS06.03 INSIGHT Study Interim Analysis: Impact of VeriStrat Results on Patient Management in Early and Locally Advanced NSCLC: Topic: Medical Oncology', Journal of Thoracic Oncology, vol. 12, no. 11. https://doi.org/10.1016/J.JTHO.2017.09.084

@article{f5fcc447dec6440e9a7cb47369e1ccde,

title = "PS06.03 INSIGHT Study Interim Analysis: Impact of VeriStrat Results on Patient Management in Early and Locally Advanced NSCLC: Topic: Medical Oncology",

author = "P.R. Walker and E. Schaefer and Rich, \{P. Thompson\} and J. Dubay and N. Ikhlaque and D. Oubre and E. Pauli and J. Orsini and E. Santos and Rose, \{A. Veatch\} and C. Jordan and R. Page and A. Arnaud and B. Mitchell",

note = "The VeriStrat{\textregistered} test (VS) is an established multivariate serum proteomic test which classifies patients with non-small cell lung cancer (NSCLC) as either VS Good or VS Poor, according to their prognosis and likelihood of response to conventional first and second line chemotherapy. The test is used to help guide treatment decisions and facilitate prognostic conversations with patients.",

year = "2017",

month = nov,

day = "1",

doi = "10.1016/J.JTHO.2017.09.084",

language = "American English",

volume = "12",

journal = "Journal of Thoracic Oncology",

number = "11",

}

TY - JOUR

T1 - PS06.03 INSIGHT Study Interim Analysis: Impact of VeriStrat Results on Patient Management in Early and Locally Advanced NSCLC: Topic: Medical Oncology

AU - Walker, P.R.

AU - Schaefer, E.

AU - Rich, P. Thompson

AU - Dubay, J.

AU - Ikhlaque, N.

AU - Oubre, D.

AU - Pauli, E.

AU - Orsini, J.

AU - Santos, E.

AU - Rose, A. Veatch

AU - Jordan, C.

AU - Page, R.

AU - Arnaud, A.

AU - Mitchell, B.

N1 - The VeriStrat® test (VS) is an established multivariate serum proteomic test which classifies patients with non-small cell lung cancer (NSCLC) as either VS Good or VS Poor, according to their prognosis and likelihood of response to conventional first and second line chemotherapy. The test is used to help guide treatment decisions and facilitate prognostic conversations with patients.

PY - 2017/11/1

Y1 - 2017/11/1

UR - https://www.jto.org/article/S1556-0864(17)30818-3/fulltext

U2 - 10.1016/J.JTHO.2017.09.084

DO - 10.1016/J.JTHO.2017.09.084

M3 - Article

VL - 12

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 11

ER -

PS06.03 INSIGHT Study Interim Analysis: Impact of VeriStrat Results on Patient Management in Early and Locally Advanced NSCLC: Topic: Medical Oncology

Disciplines

Access to Document

Other files and links

Cite this